{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:50:26Z","timestamp":1767963026907,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.09.037","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T18:06:26Z","timestamp":1505930786000},"page":"5794-5798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice"],"prefix":"10.1016","volume":"35","author":[{"given":"Dev","family":"Karan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.09.037_b0005","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA: a Cancer J Clinicians"},{"key":"10.1016\/j.vaccine.2017.09.037_b0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nrurol.2012.106","article-title":"Cancer immunotherapy: a paradigm shift for prostate cancer treatment","volume":"9","author":"Karan","year":"2012","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.09.037_b0020","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0025","first-page":"264","article-title":"Adenovirus-based immunotherapy for prostate cancer","volume":"8","author":"Dubey","year":"2012","journal-title":"Current Cancer Therapy Rev"},{"key":"10.1016\/j.vaccine.2017.09.037_b0030","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2017.09.037_b0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/hum.1990.1.3-241","article-title":"Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector","volume":"1","author":"Stratford-Perricaudet","year":"1990","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2017.09.037_b0040","article-title":"10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb","author":"Muona","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2017.09.037_b0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/15376510802312464","volume":"5","author":"Sheets","year":"2008","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2217\/imt.11.59","article-title":"Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice","volume":"3","author":"Karan","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2017.09.037_b0055","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1002\/cncr.30250","article-title":"Immunotherapy for prostate cancer: False promises or true hope?","volume":"122","author":"Rekoske","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2017.09.037_b0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2016.70.4791","article-title":"Can prostate cancer really respond to immunotherapy?","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.coi.2005.01.011","article-title":"Breaking tolerance in cancer immunotherapy: time to ACT","volume":"17","author":"Overwijk","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cellimm.2015.09.011","article-title":"Tolerance and immune suppression in the tumor microenvironment","volume":"299","author":"Ostrand-Rosenberg","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/1547691X.2013.865094","article-title":"Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy","volume":"11","author":"Rolinski","year":"2014","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bulcan.2014.12.002","article-title":"Breaking immune tolerance in cancer","volume":"102","author":"Desbois","year":"2015","journal-title":"B Cancer"},{"key":"10.1016\/j.vaccine.2017.09.037_b0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cellimm.2015.02.003","article-title":"Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer","volume":"294","author":"Zheng","year":"2015","journal-title":"Cellular Immunology"},{"key":"10.1016\/j.vaccine.2017.09.037_b0090","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1016\/j.vaccine.2006.04.022","article-title":"Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer","volume":"24","author":"Lubaroff","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.037_b0095","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ijc.22873","article-title":"Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine","volume":"121","author":"Karan","year":"2007","journal-title":"Internat J Cancer J Internat Du Cancer"},{"key":"10.1016\/j.vaccine.2017.09.037_b0100","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0105","doi-asserted-by":"crossref","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015.","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"10.1016\/j.vaccine.2017.09.037_b0110","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2017.09.037_b0115","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1089\/hum.1998.9.14-2121","article-title":"Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma","volume":"9","author":"Molnar-Kimber","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2017.09.037_b0120","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4049\/jimmunol.166.2.731","article-title":"Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix","volume":"166","author":"Siemens","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.09.037_b0125","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","article-title":"Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results","volume":"15","author":"Lubaroff","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2017.09.037_b0130","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2012-2692","article-title":"An ongoing Phase II trial of an adenovirus\/PSA vaccine for prostate cancer","volume":"72","author":"Lubaroff","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2017.09.037_b0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/0008-5472.CAN-14-2538","article-title":"Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge","volume":"75","author":"Makkouk","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2017.09.037_b0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5387\/fms.53.95","article-title":"Breakthrough of immune self-tolerance to calreticulin induced by CpG-oligodeoxynucleotides as adjuvant","volume":"53","author":"Abe","year":"2007","journal-title":"Fukushima J Med Sci"},{"key":"10.1016\/j.vaccine.2017.09.037_b0145","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2007-05-091728","article-title":"Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge","volume":"111","author":"Elzey","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2017.09.037_b0150","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1084\/jem.183.5.2129","article-title":"CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8(+) CTL response","volume":"183","author":"Borrow","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.09.037_b0155","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1126\/science.1072615","article-title":"A role for CD40 expression on CD8(+) T cells in the generation of CD8(+) T cell memory","volume":"297","author":"Bourgeois","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.09.037_b0160","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/eji.201545554","article-title":"CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells","volume":"46","author":"Trella","year":"2016","journal-title":"Eur J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T12:49:45Z","timestamp":1531572585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17312665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":32,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17312665"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}